<DOC>
	<DOCNO>NCT02819999</DOCNO>
	<brief_summary>The purpose study test effect rovalpituzumab tesirine frontline treatment small cell lung cancer ( SCLC ) .</brief_summary>
	<brief_title>A Study Rovalpituzumab Tesirine ( SC16LD6.5 ) Frontline Treatment Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Age ≥ 18 year histologically cytologicallyconfirmed , extensivestage , chemotherapynaïve SCLC DLL3expressing SCLC base central immunohistochemistry ( IHC ) assessment . Positive define stain ≥50 % tumor cell . Eastern Cooperative Oncology Group performance status 0 1 . Minimum life expectancy least 12 week . Recovery Grade 1 clinically significant toxicity ( exclude alopecia ) prior initiation study drug . Satisfactory laboratory parameter within defined parameter ( ANC , platelet count , Hb , total bilirubin , ALT , AST GFR ) Subjects history CNS metastases must complete definitive treatment prior first dose study treatment , stable dose corticosteroid Use effective contraception method 1 year follow study drug dose female childbearing potential sexually active male Prior systemic chemotherapy , small molecule inhibitor , immune checkpoint inhibitor , monoclonal antibody , antibodydrug conjugate , radioimmunoconjugates , Tcell cellbased biologic therapy , anticancer therapy treatment ( limited extensive ) SCLC . Any significant medical condition , , opinion investigator sponsor , may place subject undue risk study . Documented history cerebral vascular , unstable angina , myocardial infarction , cardiac symptom consistent New York Heart Association ( NYHA ) Class IIIIV within 6 month prior first dose study drug . Recent ongoing serious infection . Women pregnant breastfeeding . History another invasive malignancy remission least 3 year . Exceptions : nonmelanoma skin cancer , curatively treat localized prostate cancer , cervical cancer situ biopsy squamous intraepithelial lesion PAP smear . Prior exposure pyrrolobenzodiazepine ( PBD ) base drug , know hypersensitivity rovalpituzumab tesirine excipient contain drug formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>